MD Anderson designated IAEA Collaborating Centre to focus on improving radiation, radiology and nuclear medicine

A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers

As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease. The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...

January 16, 2026

Vol.52 No.02

By Kevin King

Clinical Roundup

Mutation predicts chemoresistance and better responses to immunotherapy in advanced bladder cancer, MD Anderson study finds

Researchers at The University of Texas MD Anderson Cancer Center have determined that mutations in the KDM6A gene—common in advanced bladder cancer—may serve as a predictive biomarker to determine which patients are less likely to benefit from standard chemotherapy but may respond better to immunotherapy.

January 16, 2026

Vol.52 No.02

Drugs & Targets

Kallisio partners with Stanford Health Care on rollout of Stentra system for head-and-neck radiation therapy

Kallisio has collaborated with Stanford Health Care to support the clinical implementation of its FDA-cleared Stentra system for use in head-and-neck cancer radiation therapy.

January 09, 2026

Vol.52 No.1

Drugs & Targets

SOPHiA GENETICS partners with MD Anderson on AI-driven precision oncology

SOPHiA GENETICS and The University of Texas MD Anderson Cancer Center have entered into a collaboration to accelerate data-driven cancer care through new tools that can accurately analyze, interpret, and translate diagnostic results into clinical practice.

January 09, 2026

Vol.52 No.1

Clinical Roundup

Proton vs. traditional radiation therapy significantly improves survival in head and neck cancers, MD Anderson-led study finds

Patients with oropharyngeal cancers who were treated with proton therapy, compared to traditional radiation therapy saw a significant survival benefit, according to the findings from a phase III trial led by researchers at the University of Texas MD Anderson Cancer Center.

December 19, 2025

Vol.51 No.46

In Brief

MD Anderson announces $2.5B philanthropic campaign

The University of Texas MD Anderson Cancer Center has launched a $2.5 billion comprehensive philanthropic campaign: Only Possible Here, The Campaign to End Cancer.

November 14, 2025

Vol.51 No.42

MD Anderson designated IAEA Collaborating Centre to focus on improving radiation, radiology and nuclear medicine

YOU MAY BE INTERESTED IN

A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers

Mutation predicts chemoresistance and better responses to immunotherapy in advanced bladder cancer, MD Anderson study finds

Kallisio partners with Stanford Health Care on rollout of Stentra system for head-and-neck radiation therapy

SOPHiA GENETICS partners with MD Anderson on AI-driven precision oncology

Proton vs. traditional radiation therapy significantly improves survival in head and neck cancers, MD Anderson-led study finds

MD Anderson announces $2.5B philanthropic campaign

Renew today!

Subscriber content

Never miss an issue!

Login